<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">J Thorac Oncol</journal-id>
        <journal-id journal-id-type="iso-abbrev">J Thorac Oncol</journal-id>
        <journal-id journal-id-type="pmc-domain-id">319</journal-id>
        <journal-id journal-id-type="pmc-domain">nihpa</journal-id>
        <journal-title-group>
          <journal-title>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">1556-0864</issn>
        <issn pub-type="epub">1556-1380</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>NIHPA Author Manuscripts</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC7704768</article-id>
        <article-id pub-id-type="pmcid-ver">PMC7704768.1</article-id>
        <article-id pub-id-type="pmcaid">7704768</article-id>
        <article-id pub-id-type="pmcaiid">7704768</article-id>
        <article-id pub-id-type="manuscript-id">NIHMS1620163</article-id>
        <article-id pub-id-type="pmid">32791233</article-id>
        <article-id pub-id-type="doi">10.1016/j.jtho.2020.08.005</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHMS1620163</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHPA1620163</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Caso</surname>
              <given-names initials="R">Raul</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Sanchez-Vega</surname>
              <given-names initials="F">Francisco</given-names>
            </name>
            <xref ref-type="aff" rid="A2">b</xref>
            <xref ref-type="aff" rid="A3">c</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Tan</surname>
              <given-names initials="KS">Kay See</given-names>
            </name>
            <xref ref-type="aff" rid="A4">d</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Mastrogiacomo</surname>
              <given-names initials="B">Brooke</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
            <xref ref-type="aff" rid="A3">c</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Zhou</surname>
              <given-names initials="J">Jian</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Jones</surname>
              <given-names initials="GD">Gregory D.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Nguyen</surname>
              <given-names initials="B">Bastien</given-names>
            </name>
            <xref ref-type="aff" rid="A5">e</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Schultz</surname>
              <given-names initials="N">Nikolaus</given-names>
            </name>
            <xref ref-type="aff" rid="A5">e</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Connolly</surname>
              <given-names initials="JG">James G.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Brandt</surname>
              <given-names initials="WS">Whitney S.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bott</surname>
              <given-names initials="MJ">Matthew J.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
            <xref ref-type="aff" rid="A6">f</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Rocco</surname>
              <given-names initials="G">Gaetano</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
            <xref ref-type="aff" rid="A6">f</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Molena</surname>
              <given-names initials="D">Daniela</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
            <xref ref-type="aff" rid="A6">f</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Isbell</surname>
              <given-names initials="JM">James M.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
            <xref ref-type="aff" rid="A6">f</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Liu</surname>
              <given-names initials="Y">Yuan</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
            <xref ref-type="aff" rid="A6">f</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Mayo</surname>
              <given-names initials="MW">Marty W.</given-names>
            </name>
            <xref ref-type="aff" rid="A7">g</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Adusumilli</surname>
              <given-names initials="PS">Prasad S.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
            <xref ref-type="aff" rid="A6">f</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Travis</surname>
              <given-names initials="WD">William D.</given-names>
            </name>
            <xref ref-type="aff" rid="A6">f</xref>
            <xref ref-type="aff" rid="A8">h</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Jones</surname>
              <given-names initials="DR">David R.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
            <xref ref-type="aff" rid="A6">f</xref>
          </contrib>
        </contrib-group>
        <aff id="A1"><label>a</label>Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 USA</aff>
        <aff id="A2"><label>b</label>Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 USA</aff>
        <aff id="A3"><label>c</label>Computational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 USA</aff>
        <aff id="A4"><label>d</label>Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 USA</aff>
        <aff id="A5"><label>e</label>Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 USA</aff>
        <aff id="A6"><label>f</label>Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 USA</aff>
        <aff id="A7"><label>g</label>Department of Biochemistry &amp; Molecular Genetics, University of Virginia, P.O. Box 800733, Charlottesville, VA 22908 USA</aff>
        <aff id="A8"><label>h</label>Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 USA</aff>
        <author-notes>
          <corresp id="CR1"><bold>Corresponding author:</bold> David R. Jones, MD, Professor &amp; Chief, Thoracic Surgery Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 7, New York, NY 10065, Phone: 212-639-6428, Fax: 232-639-6686, <email>jonesd2@mskcc.org</email></corresp>
          <fn fn-type="COI-statement" id="FN1">
            <p id="P39"><bold>Conflicts of Interest:</bold> Matthew J. Bott is a consultant for AstraZeneca. Gaetano Rocco has financial relationships with Scanlan. Daniela Molena is a consultant for Intuitive, Boston Scientific, Johnson and Johnson and Urogen. James M. Isbell has stock ownership in LumaCyte and is a consultant/advisory board member for Roche Genentech. Prasad S. Adusumilli has received research funding and fees from ATARA Biotherapeutics, has a licensed patent on mesothelin-targeted CAR, and pending patent applications on T-cell therapies. He serves as a consultant and on the scientific advisory board for Bayer, Carisma Therapeutics, Imugene, and Takeda Therapeutics. William D. Travis is a consultant and in the speaker’s bureau for Genentech. David R. Jones serves as a senior medical advisor for Diffusion Pharmaceuticals and a consultant for AstraZeneca and Merck. All other authors have no disclosures.</p>
          </fn>
        </author-notes>
        <pub-date pub-type="epub">
          <day>10</day>
          <month>8</month>
          <year>2020</year>
        </pub-date>
        <pub-date pub-type="ppub">
          <month>12</month>
          <year>2020</year>
        </pub-date>
        <volume>15</volume>
        <issue>12</issue>
        <issue-id pub-id-type="pmc-issue-id">369808</issue-id>
        <fpage>1844</fpage>
        <lpage>1856</lpage>
        <pub-history>
          <event event-type="nihms-submitted">
            <date>
              <day>16</day>
              <month>08</month>
              <year>2020</year>
            </date>
          </event>
          <event event-type="pmc-release">
            <date>
              <day>01</day>
              <month>12</month>
              <year>2021</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>01</day>
              <month>12</month>
              <year>2021</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2024-06-16 21:25:30.187">
              <day>16</day>
              <month>06</month>
              <year>2024</year>
            </date>
          </event>
        </pub-history>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1620163.pdf"/>
        <related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="commentary" xml:lang="en" xlink:title="article-commentary" journal-id="J Thorac Oncol" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC8532170">
          <article-title>Response to the Letter to the Editor: Clinical and Pathological
Implications of Tumor Genomics of Predominant Histologic Subtypes in Lung
Adenocarcinoma</article-title>
          <volume>15</volume>
          <issue>12</issue>
          <date>
            <month>12</month>
            <year>2020</year>
          </date>
          <fpage>e188</fpage>
          <lpage>e189</lpage>
          <source>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</source>
          <pub-id pub-id-type="pmcid">PMC8532170</pub-id>
          <pub-id pub-id-type="pmid">33246597</pub-id>
        </related-article>
        <abstract id="ABS1">
          <sec id="S1">
            <title>Introduction:</title>
            <p id="P1">The purpose of the study is to genomically characterize the biology and related therapeutic opportunities of prognostically important predominant histological subtypes in lung adenocarcinoma (LUAD).</p>
          </sec>
          <sec id="S2">
            <title>Methods:</title>
            <p id="P2">We identified 604 patients with stage I-III LUAD who underwent complete resection and targeted next-generation sequencing using the MSK-IMPACT platform. Tumors were classified according to predominant histologic subtype and grouped by architectural grade (lepidic [LEP], acinar or papillary [ACI/PAP], and micropapillary or solid [MIP/SOL]). Associations between clinicopathologic factors, genomic features, mutational signatures, and recurrence were examined within subtypes and, when appropriate, quantified using competing-risks regression, with adjustment for pathologic stage and extent of resection.</p>
          </sec>
          <sec id="S3">
            <title>Results:</title>
            <p id="P3">MIP/SOL tumors had higher tumor mutational burden (<italic toggle="yes">p</italic>&lt;0.001), fraction of genome altered (<italic toggle="yes">p</italic>=0.001), copy number amplifications (<italic toggle="yes">p</italic>=0.021), rate of whole-genome doubling (<italic toggle="yes">p</italic>=0.008), and number of oncogenic pathways altered (<italic toggle="yes">p</italic>&lt;0.001), compared with LEP and ACI/PAP tumors. Across all tumors, mutational signatures attributed to APOBEC activity were associated with the highest risk of postresection recurrence: SBS2 (<italic toggle="yes">p</italic>=0.021) and SBS13 (<italic toggle="yes">p</italic>=0.005). Three oncogenic pathways (p53, Wnt, Myc) were altered with statistical significance in MIP/SOL tumors. Compared with LEP and ACI/PAP tumors, MIP/SOL tumors had a higher frequency of targetable <italic toggle="yes">BRAF</italic>-V600E mutations (<italic toggle="yes">p</italic>=0.046). Among ACI/PAP tumors, alterations in the cell cycle (<italic toggle="yes">p</italic>&lt;0.001) and PI3K (<italic toggle="yes">p</italic>=0.002) pathways were associated with recurrence; among MIP/SOL tumors, only PI3K alterations were (<italic toggle="yes">p</italic>=0.049).</p>
          </sec>
          <sec id="S4">
            <title>Conclusions:</title>
            <p id="P4">These results provide the first in-depth assessment of tumor genomic profiling of predominant LUAD histologic subtypes, their associations with recurrence, and their correlation with targetable driver alterations in patients with surgically resected LUAD.</p>
          </sec>
        </abstract>
        <kwd-group>
          <kwd>Lung adenocarcinoma</kwd>
          <kwd>Histologic subtypes</kwd>
          <kwd>Next-generation sequencing</kwd>
        </kwd-group>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
